Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be able and willing to give written informed consent prior to any study related procedures~2. Ambulatory, female patients with an age ≥ 18 years~3. Patients with histologically or cytologically proven diagnosis of breast cancer who are eligible for neoadjuvant or adjuvant chemotherapy.~4. Patients who are planned and eligible to receive/ receiving myelosuppressive chemotherapy regimen that contains at least one chemotherapeutic agent from docetaxel/ paclitaxel / doxorubicin/ cyclophosphamide/ epirubicin~5. Patients who have not received any hematopoietic growth factors (e.g. G-CSF, PegGCSF, erythropoietin) or cytokines (e.g. interleukins, interferons) anytime in the past~6. Patients with baseline WBC ≥ LLN/ 3.5 x 109/L, ANC of ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L and hemoglobin ≥ 8.5 g/dL~7. Patients with ECOG Performance status of ≤ 2~8. Patient who have estimated life expectancy of more than six months~9. No evidences of hemorrhage~Exclusion Criteria:~1 Male patients~2. Hypersensitivity to any of the study drugs or its components like E.coli proteins or similar product~3. Patients weighing \<45 Kg~4. Patients with myeloid malignancies and myelodysplasia or evidence of metastatic disease in bone marrow or brain~5. Patients currently receiving radiation therapy or have completed radiation therapy within 4 weeks before study entry or likely to receive radiotherapy during the study~6. Patients with prior bone marrow or stem cell transplantation~7. Patients with chronic use of oral corticosteroids (Except ≤ 20 mg/day dose of prednisolone/ equivalent steroids), immunotherapy, monoclonal antibody therapy and/or biological therapy or use of any other pegylated drug.~8. Patients with history of systemic antibiotic use within 72 hours prior to chemotherapy~9. Patients with any active infection which may require systemic antimicrobial therapy. Patients with inadequate hepatic and renal function \[defined as Alkaline Phosphatase \> 2.5 X Upper limits of normal (ULN), serum SGOT \> 2.5 X ULN, SGPT \> 2.5 X ULN, Total bilirubin \> 1.5 X ULN and Creatinine \> 1.5 X ULN of the reference range at the screening assessment\]~10. Patients with seropositivity for HIV or HBV or HCV~11. Known cases of Sickle Cell Anemia~12. Patients with radiographic evidence of active pulmonary infections and/or recent history of pneumonia within 1 month of screening~13. Patients with clinically evident splenomegaly confirmed subsequently by ultrasonography~14. Patients with any other clinically significant disease(s) which, in the opinion of the investigator, could compromise the patient's involvement in the study or overall interpretation of the data. \[for e.g. uncontrolled hematologic, renal, hepatic, endocrine, neurologic, psychiatric, metabolic, pulmonary, cardiovascular disease/impaired functioning or history of any autoimmune disease\]~15. Patients who have participated in another therapeutic clinical study within the past 30 days prior to screening, or are likely to simultaneously participate in another therapeutic clinical study~16. Patients who are doubtful to comply with study procedures for mental, psychological or social reasons.~17. Women of child-bearing potential who are not willing to follow a reliable \& effective contraceptive measure during the course of the study \& at least 3 months after the last dose of study drug.~18. Pregnant and Breast feeding women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lupin's Pegfilgrastim (Type: EXPERIMENTAL): 6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
- Neulasta® (Type: EXPERIMENTAL): 6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).